Home › Ewing Sarcoma › Ohio › Cincinnati
Ewing Sarcoma clinical trials in Cincinnati, OH
5 studies for Ewing Sarcoma are looking for participants at sites in and around Cincinnati (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
RecruitingPhase 1/2
- Cincinnati Children's Hospital Medical Center, Cincinnati
Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors
RecruitingPhase 1
- Cincinnati Children's Hospital Medical Center, Cincinnati
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
RecruitingPhase 1
- Cincinnati Children's Hospital Medical Center, Cincinnati
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
RecruitingPhase 1/2
- Cincinnati Children's Hospital Medical Center, Cincinnati
Single Arm Romiplostim to Prevent CIT
RecruitingEarly phase 1
- Cincinnati Children's Hospital Medical Center, Cincinnati
Ewing Sarcoma trials in other cities
- New York City, NY8 studies
- Houston, TX7 studies
- Memphis, TN7 studies
- Philadelphia, PA7 studies
- Los Angeles, CA6 studies
- Washington, DC6 studies
- Aurora, CO6 studies
- Boston, MA6 studies
- Birmingham, AL5 studies
- Atlanta, GA5 studies
- Nashville, TN4 studies
- Gainesville, FL4 studies
Other studies in Cincinnati
- Non-Small Cell Lung Cancer31 studies
- Cancer (all types)26 studies
- Breast Cancer24 studies
- Heart Failure22 studies
- Metastatic Cancer21 studies
- Colorectal Cancer20 studies
- Obesity20 studies
- Acute Myeloid Leukemia20 studies
- Prostate Cancer19 studies
- Ovarian Cancer18 studies
- Lung Cancer18 studies
- Multiple Myeloma17 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.